Controlled-release Drug Delivery Technologies:
Players, products & prospects to 2015
| Price: £595.00 Approx $1,155.49 (USD) €888.70 (EUR) |
|
|---|---|
| Overview: | |
| The controlled-release market is estimated to be worth over US$17 billion globally in 2007. Delivery specialists estimate that oral-dosage controlled-release delivery systems contribute the majority of sales around 90% and demonstrated +2% year-on-year growth. By 2015, the report forecasts that controlled-release products in development from 22 key companies could generate additional sales of over US$11.7 billion. These products utilise a range of delivery platforms including diffusion, degradation and activated controlled-release systems. The world is likely to become a smarter place as site specific controlled-release technologies become a reality. Opportunities now... While the growth of controlled-release technology continues to be fuelled by line extensions helping to offset the impact of generic erosion this market is far from being exhausted. Many pharmaceutical companies have yet to make the additional investment to develop a controlled-release version of a product while the immediate-release version is under patent protection. Therefore, considerable market opportunities still exist in the development and application for precise, controlled-delivery products for both approved and new pharmaceuticals. ...and in the future Controlled-release technologies are increasingly being applied in the preclinical development of products, leading to the parallel development of immediate-release and controlled-release formulations to maximise market exposure. Controlled-release formulations may potentially provide for greater effectiveness in the treatment of chronic conditions through more predictable kinetics; reduced side effects by minimising peak plasma concentrations; greater convenience and higher levels of patient compliance due to a simplified dosage schedule. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr Cheryl Lee Barton / Publication Date: 17th November 2007
Contents:
Contents
EXECUTIVE SUMMARY 1
Competitor Ratio Analysis Summary 4
Introduction 7
Overview of controlled-release delivery : past , present & future 8
Controlled-Release delivery: motivators & resistors 9
Motivators 9
Resistors 9
Controlled-Release delivery: impact on product lifecycles 10
CONTROLLED-RELEASE DELIVERY 11
Types of controlled-release delivery used by pharma industry 11
Activated controlled-release delivery 11
Figure 1: Activated controlled-release delivery – ALZA’s OROS systems 11
Degradation controlled-release delivery 12
Figure 2: Degradation controlled-release delivery – SkyePharma’s GEOMATRIX 12
Diffusion controlled-release delivery 13
Figure 3: Monolithic diffusion controlled-release delivery – LaboPharm’s Contramid 13
Figure 4: Reservoir diffusion controlled-release delivery – Impax’ CMDS 13
Figure 5: Combined controlled-release delivery – Flamel’s Micropump 14
Table 1: Advantages and disadvantages of controlled-release platforms 15
Current therapeutic application of controlled-release in drug delivery 15
Leading brands that utilise controlled-release delivery 16
Table 2: Controlled-Release approved drugs 16
Future commercial applications & opportunities 16
STRATEGIES OF DRUG DELIVERY COMPANIES 18
Leading controlled-release drug delivery companies 18
Table 3: Leading controlled-release drug delivery companies 18
Partnerships & acquisitions 20
Strategic developmental & commercialisation partnerships 20
Merger & acquisitions 21
Table 4: Recent partnerships & acquisitions in the controlled-release field 21
Intellectual Property 24
Table 5: Controlled-Release patents 24
THE controlLed-release MARKET 25
Now 2007 25
Table 6: Approved controlled-release product sales 25
Future 2015 25
Table 7: Global controlled-release product sales 26
Table 8: Novel controlled-release product sales 26
Movers & Shakers: Cutting edge or losing their grip 27
Table 9: Movers & shakers in controlled-release drug delivery systems 28
COMPANY PROFILES 29
AlphaRx Corporation (www.alpharx.com) 29
Table 10: AlphaRx’ product pipeline 30
Table 11: AlphaRx’ drug delivery sales 30
ALZA Corporation (www.alza.com) 32
Table 12: ALZA’s product pipeline 35
Andrx Corporation (www.watsonandandrx.com) 37
Table 14: Andrx’ product pipeline 39
Table 15: Andrx’ drug delivery sales 39
Antares Pharma, Inc. (www.antarespharma.com) 40
Table 16: Antares’ product pipeline 41
Table 17: Antares’ drug delivery sales 42
Biovail International (www.biovail.com) 43
Table 18: Biovail’s product pipeline 45
Table 19: Biovail’s drug delivery sales 46
Camurus AB (www.camurus.se) 47
Table 20: Camurus AB’s product pipeline 48
Table 21: Camurus AB’s drug delivery sales 48
Cipher Pharmaceuticals, Inc. (www.cipherpharma.com 49
Table 22: Cipher’s product pipeline 49
Table 23: Cipher’s drug delivery sales 50
Debiopharm (www.debio.com) 51
Table 24: Debiopharm’s product pipeline 52
Table 25: DebioPharm’s drug delivery sales 52
DelSite Biotechnologies, Inc. (www.delsite.com) 54
Table 26: DelSite’s product pipeline 55
Depomed, Inc. (www.depomedinc.com) 56
Table 27: Depomed’s product pipeline 58
Table 28: Depomed’s product sales 58
Durect Corporation (www.durect.com) 60
Table 29: Durect’s product pipeline 62
Table 30: Durect’s product sales 63
Eiffel Technologies (www.eiffeltechnologies.com.au) 64
Table 31: Eiffel’s product pipeline 65
Elan Corporation (www.elan.com) 66
Table 32: Elan’s product pipeline 67
Table 33: Elan’s drug delivery sales 68
Elite Pharmaceuticals, Inc. (www.elitepharma.com) 69
Table 34: Elite’s product pipeline 70
Table 35: Elite’s product sales 70
Endo Pharmaceuticals, Inc. (www.endo.com) 72
Table 36: Endo’s product pipeline 73
Table 37: Endo’s product sales 73
Ethypharm SA (www.ethypharm.com 75
Table 38: Ethypharm’s product pipeline 76
Table 39: Ethypharm’s product sales 76
Eurand (www.eurand.com 78
Table 40: Eurand’s product pipeline 80
Table 41: Eurand’s product sales 81
Flamel Technologies, Inc. (www.flamel.com) 82
Table 42: Flamel’s product pipeline 83
Table 43: Flamel’s product sales 83
Glycologic, Ltd (www.glycologic.co.uk) 85
Table 44: Glycologic’s product pipeline 86
Impax Laboratories, Inc. (www.impaxlabs.com) 87
Table 45: Impax’ product pipeline 89
Table 46: Impax’s product sales 89
Table 47: KV’s product pipeline 91
Labopharm, Inc. (www.labopharm.com) 92
Table 48: Labopharm’s product pipeline 93
Table 49: Labopharm’s product sales 93
Lavipharm SA (www.lavipharm.com) 95
Table 50: Lavipharm’s product pipeline 96
Table 51: Lavipharm’s product sales 96
OctoPlus N.V. (www.octoplus.nl 98
Table 52: Octoplus’ product pipeline 99
Table 53: Octoplus’ product sales 99
Penwest Pharmaceuticals (www.penw.com) 100
Table 54: Penwest’s product pipeline 102
Table 55: Penwest’s product sales 102
Protherics (www.protherics.com )104
Table 56: Protherics’ product pipeline 105
Table 57: Protherics’ drug delivery sales 106
SCOL R Pharma, Inc. (www.scolr.com) 107
Table 58: SCOLR’s product pipeline 108
Table 59: SCOLR’s drug delivery sales 108
Shire (www.shire.com) 110
Table 60: Shire’s product pipeline 111
Table 61: Shire’s drug delivery sales 112
Skinvisible, Inc. (www.skinvisible.com) 113
Table 62: Skinvisible’s product pipeline 114
SkyePharma (www.skyepharma.com) 115
Table 63: SkyePharma’s CR product pipeline 116
Table 64: SkyePharma’s controlled-release product sales 117
Spherics (www.spherics.com) 118
Table 65: Spheric’s product pipeline 119
APPENDIX 1 120
Table 66: Global controlled-release approved drugs sales 2006A-20015E 120
APPENDIX 2 123
Table 67: Global controlled-release developmental drugs sales 2006A-20015E 123
APPENDIX 3 126
Competitor Ratio Analysis Criteria 126
Table 68: Key Controlled-Release delivery companies by 2015 127
BIBLIOGRAPHY 129
GLOSSARY 130
ACRONYMS 132
Table of Contents